论文部分内容阅读
目的观察补脾、醒脾药物对饮食诱导肥胖(DIO)大鼠肥胖及瘦素抵抗的影响。方法 Wister大鼠120只,制作DIO大鼠40只和DIO-R大鼠10只,DIO大鼠分为DIO模型组、西布曲明组、醒脾组、补脾气组4组,分别以生理盐水、西布曲明、醒脾药物(藿香、佩兰、高良姜)、补脾气药物(白术、云苓、黄芪)灌胃,空白对照组与DIO-R组予生理盐水。灌胃16周后,测定体重,神经肽(NPY)、血清和脂肪匀浆中瘦素(leptin),脂肪匀浆中细胞因子转录负调节因子(SOCS-3)。结果 DIO模型组与DIO-R组比较,体重、NPY明显升高,血清和脂肪匀浆瘦素降低(P<0.05),SOCS-3升高(P<0.05,P<0.01)。药物干预后,各药物组体重有所下降。补脾气组治疗后体重、体重差值、NPY(P<0.01)、SOCS-3水平(P<0.05)减低,血清和脂肪匀浆瘦素水平升高(P<0.01),且在体重减低,血清瘦素升高方面明显优于西布曲明和醒脾组。结论 DIO大鼠存在瘦素抵抗,补脾药物能减轻肥胖,提高瘦素水平,抑制瘦素抵抗。
Objective To observe the effects of BuBu and XingpiXing on obesity and leptin resistance in diet-induced obesity (DIO) rats. Methods 120 Wister rats, 40 DIO rats and 10 DIO-R rats were made. DIO rats were divided into 4 groups: DIO model group, sibutramine group, xupu spleen group, , Sibutramine, awake spleen drug (Agastache rugosa, Perrin, galangal), BuBuQi medicine (Atractylodes, Yunling, Astragalus) were given orally, and blank control group and DIO-R group were given normal saline. After 16 weeks of gavage, body weight, neuropeptide (NPY), leptin in serum and fat homogenate, and negative regulator of cytokine transcription (SOCS-3) in fat homogenate were determined. Results Compared with DIO-R group, the weight and NPY of DIO model group were significantly increased. The serum and fat homogenate leptin decreased (P <0.05) and SOCS-3 increased (P <0.05, P <0.01). After drug intervention, body weight of each drug group decreased. The body weight, weight difference, NPY (P <0.01), SOCS-3 level (P <0.05) and leptin level in serum and fat homogenate increased (P <0.01) Serum leptin was significantly better than sibutramine and awake spleen group. Conclusion There is leptin resistance in DIO rats, which can reduce obesity, increase leptin level and inhibit leptin resistance.